Integra Lifesciences Holdings (IART) Long-Term Debt Issuances (2010 - 2026)

Integra Lifesciences Holdings has disclosed Long-Term Debt Issuances across 16 years of filings, most recently posting $44.5 million for Q1 2026.

• Long-Term Debt Issuances for Q1 2026 came in at $44.5 million, down 18.2% year-over-year; the trailing twelve-month figure through Mar 2026 was $710.8 million (up 317.14% YoY), and the FY2025 annual result was $720.7 million, up 48.14% from the prior year.
• Long-Term Debt Issuances came in at $44.5 million for Q1 2026 at Integra Lifesciences Holdings, down from $49.7 million in the prior quarter.
• In the past five years, Long-Term Debt Issuances ranged from a high of $603.7 million in Q3 2025 to a low of $5.0 million in Q2 2023.
• The 5-year median for Long-Term Debt Issuances is $21.8 million (2024), against an average of $85.7 million.
• Across the five-year window, Long-Term Debt Issuances jumped 3532.35% in 2024 and plunged 85.32% in 2025, its largest moves.
• Integra Lifesciences Holdings' Long-Term Debt Issuances stood at $6.5 million in 2022, then surged by 180.0% to $18.2 million in 2023, then surged by 94.51% to $35.4 million in 2024, then surged by 40.4% to $49.7 million in 2025, then retreated by 10.46% to $44.5 million in 2026.
• The last three Long-Term Debt Issuances figures came in at $44.5 million (Q1 2026), $49.7 million (Q4 2025), and $603.7 million (Q3 2025), per Business Quant data.